The Development Of COVID-19 Treatment Regimen (Article Review )
DOI:
https://doi.org/10.46966/msjar.v4i2.134Keywords:
COVID-19, Systemic Corticosteroids Drug , Antiviral MedicationsAbstract
Background: Since December 2019, a new human coronavirus outbreak has spread across various nations, causing numerous cases and deaths. COVID-19 is a disease caused by the brand-new SARS-CoV-2 virus (a brand-new stress of coronavirus). Wuhan, Hubei Province, People's Republic of China, is a ten-million-person metropolis. The cornerstone and most important management strategy for clinical management of COVID-19 remains early adjunct care and monitoring, which includes O2 supplementation, organ support, and interference of complications, particularly acute respiratory distress syndrome, organ failure, and secondary health facility infections.
Conclusion: COVID-19 is a pandemic that is causing an increase in the number of infections and deaths. In response to the epidemic, many pharmacologic medicines are being utilized off-label or evaluated for therapy around the world. Antiviral medications (eight drugs), antimalarial drugs (two drugs), systemic corticosteroids (five drugs), and immune-based therapy are the four primary groups of drugs suggested in treatment guidelines around the world (seven drugs). There is a lot of difference between these rules in general. These mostly dealt with drug indications, types of pharmaceuticals, dose regimens, treatment periods, and drug safety in various patient groups
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rdhwan M. Hussein, Zainab Sajid Mohammed, Hawraa Natiq Kabroot AL-Fatlawy; Asst.Prof.Dr. Wijdan Rajh Hamza Al-Kraity
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
